Collaterals at Angiography and Outcomes in the Interventional Management of Stroke (IMS) III Trial
David S Liebeskind, Thomas A Tomsick, Lydia D Foster, Sharon D Yeatts, Janice Carrozzella, Andrew M Demchuk, Tudor G Jovin, Pooja Khatri, Ruediger von Kummer, Rebecca M Sugg, Osama O Zaidat, Syed I Hussain, Mayank Goyal, Bijoy K Menon, Firas Al Ali, Bernard Yan, Yuko Y Palesch, Joseph P Broderick
Stroke | LIPPINCOTT WILLIAMS & WILKINS | Published : 2014
Awarded by National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS)
Awarded by NIH/NINDS
Awarded by Alberta Innovates
Awarded by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
This work has been funded by National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) awards P50NS044378, K24NS072272, R01NS077706, and R13NS082049. IMS III funding included NIH/NINDS awards U01NS052220, U01NS054630, and U01NS077304. Genentech Inc supplied the study drug for intra-arterial t-PA in the endovascular group. EKOS Corp, Concentric Inc, and Cordis Neurovascular Inc supplied study catheters during Amendments 1 to 3. In Europe, IMS III investigator meeting support was provided in part by Boehringer Ingelheim.